Connect with us

Media OutReach

Esco Lifesciences Group Announces Acquisition of Allwin Medical

Published

on

SINGAPORE – Media OutReach Newswire – 21 April 2026 – Esco Lifesciences Group (“Esco”) today announced the acquisition of Allwin Medical Devices, Inc., a leading manufacturer of ART/IVF consumables. Allwin Medical will continue to operate under its established brand and will become a key pillar within Esco’s Medical portfolio, alongside Esco Medical, further strengthening Esco’s global position in reproductive medicine.

The acquisition reinforces Esco’s strategy and commitment to deliver integrated ART/IVF workflow solutions—combining advanced equipment, time lapse imaging, high-quality consumables, digital traceability and witnessing, and AI-enabled embryo assessment and clinical support into a unified platform for fertility clinics worldwide.

“We are honored that Mr. Dhiren Mehta has chosen Esco as the long-term home for Allwin Medical,” said XQ Lin, Chairman & CEO of Esco Lifesciences Group. “Allwin has built a strong foundation in quality, innovation, and customer trust. Together, we will accelerate its international growth while preserving the values and legacy that define the company. With Allwin, we all win.”

Esco also extends its sincere appreciation to Mr. Dhiren Mehta, Founder of Allwin Medical, for his leadership and partnership.

“The integration of Allwin Medical with Esco Lifesciences Group represents a strategic milestone in Allwin Medical’s evolution and long-term growth trajectory. This collaboration reflects a strong alignment in vision, capabilities, and commitment to the ART/IVF sector.” said Mr. Dhiren Mehta. “This partnership enables Allwin Medical to leverage Esco’s global infrastructure, technological expertise, and international reach, while continuing to build on its established market position and specialized capabilities. We believe that the combined strengths of both organizations will support accelerated growth, expanded global presence, and enhanced value delivery to clinicians and patients, while reinforcing Allwin Medical’s commitment to quality, innovation, and customer relationships.”

Allwin Medical’s operations and team will continue to play a central role in driving growth within Esco’s Medical business unit. Headquartered in Anaheim, California, USA,and with Indian operation in Mumbai and Surat, Allwin Medical will serve as a key operating node and the India headquarters for Esco’s Medical business unit, supporting further expansion in one of the world’s fastest-growing healthcare markets.

This acquisition marks another step in Esco’s vision to build a comprehensive platform enabling ART/IVF clinics to operate more efficiently, safely, and intelligently, ultimately improving patient outcomes.

As part of its long-term vision, Esco has positioned itself as a trusted partner and permanent home for small and medium sized businesses in the life sciences and fertility tools sector—providing continuity, global commercial reach, and operational support while preserving the entrepreneurial spirit and legacy of each company.

Hashtag: #Esco

The issuer is solely responsible for the content of this announcement.

About Allwin Medical

Allwin Medical is a leading manufacturer of a wide range of medical devices including Women’s Health (IVF) and Urology. Headquartered in Anaheim, California, USA, the company is committed to providing its customers with high quality devices. Its products are sold in 130+ countries globally through a network of distributors that cater to global markets. Within India, 100+ dealers support and promote sales for the Indian market. Founded in 1998 by Dhiren Mehta, who has more than 39 years of experience in the medical device industry, the company has exhibited consistent and strong growth.

About Esco Lifesciences Group

Esco Lifesciences Group is a world-leading manufacturer of laboratory, pharmaceutical equipment, bioprocess tools and IVF medical devices, delivering sustainable workflow solutions to advance global health. Since 1978, the Singapore-based company is committed to excellence, ensuring forward-thinking technology, responsive support, and reliability, making Esco a trusted partner for the life science and medical markets in more than 150 countries.

Esco, through its Medical business unit, leads in delivering comprehensive workflow solutions for assisted reproduction technologies (ART) to IVF clinics, laboratories, and research centers worldwide.

For more information about Esco Lifesciences Group:

Media OutReach

New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction

Published

on

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore’s multi-ethnic population. His study included diverse case profiles. Results revealing no complications and high satisfaction prove the need to adapt surgical techniques for variations in skin type between Asian and Caucasian patients.

SINGAPORE – Media OutReach Newswire – 3 June 2026 – The evaluation and management of surgical treatment for gynecomastia primarily focus on Western populations. However, Amaris B. Clinic’s decades of experience in Singapore highlight specific considerations for Asian patients.

Dr Ivan Puah, Medical Director at Amaris B. Clinic and the lead researcher on a recent study, has offered new insights into treating gynecomastia, a condition characterised by male breast enlargement, in Singapore.

The research paper titled ‘Surgical Management of Gynecomastia in Asian Men – Clinical Experience and Considerations for Different Patient Types’ provides detailed, important considerations, including the management of the consultation process, addressing varying patient expectations, and tackling the surgical aspects necessary to achieve desired aesthetic outcomes.

Between 2018 and 2023, Dr Puah treated over 550 cases at Amaris B. Clinic and presented six representative patient cases that illustrate the demographics and unique challenges faced by this multi-ethnic Asian population.

The typical patient profiles included obese, overweight, and lean adults, as well as adolescents. Common causes of gynecomastia observed in the patients included hormonal changes during puberty, drug-induced gynecomastia from anabolic steroids, and conditions related to weight loss.

Dr Puah’s proprietary surgical methods involve making a single incision along the areola to minimise scar visibility while effectively excising glandular tissue, performing liposuction to remove excess fat, and tightening the chest skin.

Six case studies of diverse gynecomastia patient profiles

Gynecomastia Grade Demographic Profile
Grade II 17-year-old Chinese
  • A history of bilateral breast enlargement since 13 years-old
Grade II 18-year-old Chinese
  • A history of bilateral breast enlargement since 12 years-old
Grade II 22-year-old Malay
  • Using anabolic hormone supplements for bodybuilding for 4 years
Grade II 46-year-old Chinese
  • Took anabolic steroids for 5 years
Grade IV 28-year-old Chinese
  • Overweight since childhood
  • No reduction in breast enlargement despite losing weight
  • Skin laxity present
Grade IV 21-year-old Indian
  • Overweight since childhood
  • No reduction in breast enlargement despite losing weight
  • Skin laxity present

At the 3-month follow-up after surgery, 5 of 6 patients reported no complications, highlighting the effectiveness of the tailored surgical approach. They expressed high satisfaction with the aesthetic results of the procedure, rating it a perfect 7 out of 7, and reported relief from emotional distress.

Only one patient experienced mild keloid formation at the edges of both areolae where incisions were made, which were not easily noticeable, and reported no complications or dissatisfaction.

Dr Ivan Puah emphasises, “It is important to adapt surgical techniques to address issues such as scarring and hyperpigmentation, which can be more pronounced in Asian patients due to their skin types. The differences in skin quality and glandular tissue characteristics between Asian and Caucasian patients with gynecomastia necessitate distinctions in treatment planning, particularly regarding careful incision placement.”

The full paper is available via World Journal of Plastic Surgery at https://pmc.ncbi.nlm.nih.gov/articles/PMC12843043/


  • ABOUT DR IVAN PUAH

    Dr Puah, an MOH-accredited liposuction doctor with extensive training in various cosmetic procedures, is committed to providing personalised care with an artful eye and proven medical techniques.

    • Dedicated surgical training in gynecomastia surgery in San Francisco
    • Chairman of the Lipo Peer Review Committee in Singapore
    • Trained in Vaser liposuction (fundamental and hi-definition) in Colorado and Argentina
    • Trained in syringe liposculpture, fat grafting, and thread lift from renowned French plastic surgeon, Dr Pierre Francois Fournier
    • Appointed trainer by Allergan and Merz for fellow doctors on cosmetic injectables
    • Designated trainer for PDO thread lift and Picolaser from Venusys Medical
    • Graduate Diploma in Family Dermatology from NUS
    • Graduate Diploma in Acupuncture from TCMB
    • Graduate Diploma in Sports Medicine from LKCMedicine, NTU

    Continue Reading

    Media OutReach

    The Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity

    Published

    on

    Jean-Jacques Muyembe and Peter Piot are being honored with the international award of €500,000 for exceptional life-long leadership spanning five decades since the first outbreak of Ebola

    BERLIN, GERMANY – Newsaktuell – 2 June 2026 – The Virchow Prize 2026 has been jointly awarded to Jean‑Jacques Muyembe and Peter Piot for their pioneering and enduring leadership in the discovery, control, and understanding of epidemic threats, and for advancing equitable, multilateral cooperation and governance that have fundamentally strengthened global preparedness and solidarity in the face of infectious disease outbreaks.

    The Virchow Prize Laureates 2026: Jean-Jacques Muyembe (DR Congo) and Peter Piot (Belgium), honored for their pioneering and enduring leadership in the discovery, control, and understanding of epidemic threats, and for advancing equitable, multilateral cooperation and governance that have fundamentally strengthened global preparedness and solidarity in the face of infectious disease outbreaks.

    The announcement was made today by the Virchow Foundation which is granting the annual award. The selection of the laureates by the independent Virchow Prize Committee was preceded by a nomination period that ended on February 28, followed by a three-month deliberation period.

    This moment resonates with particular historical gravity: 2026 marks both fifty years since the emergence of Ebola and a renewed confrontation with the virus through the current outbreak and unpreparedness.

    According to the committee, the careers of Jean‑Jacques Muyembe and Peter Piot are anchored in a defining moment of modern infectious disease history: the first identified Ebola outbreak in 1976. Their collaboration demonstrated the necessity of crossing contextual, disciplinary and geographic boundaries, highlighting both the potential and the inequities inherent in global health partnerships. Over the decades, both Muyembe and Piot have worked – partly closely together, partly independent from each other in complementary ways – to transform epidemic research in an exemplary manner, firmly rooted in equity, reciprocity, and shared leadership.

    Taken together, the laureates’ contributions illustrate a continuum that is central to advancing health for all: from discovery to delivery, from local response to global coordination, from emergency action to long-term system strengthening. Their work has directly improved the ability to detect, understand, and control deadly outbreaks, while also influencing broader frameworks for addressing global health challenges in a manner that is equitable and inclusive.

    By awarding the Virchow Prize 2026 equally to Muyembe and Piot, their scientific achievements and their commitment to strengthening health systems and fostering global solidarity are honored. The laureates’ work embodies Rudolf Virchow’s legacy that health is inseparable from social organisation, governance, and collective responsibility.

    Full Article and detailed Virchow Prize Committee jury rationale at www.virchowprize.org/vp2026

    Contact: Virchow Foundation | Dorotheenstr. 83 | DE-10117 Berlin, Germany | pr***@*****ow.foundation

    The issuer is solely responsible for the content of this announcement.

    Continue Reading

    Media OutReach

    HKUST Unicorn Day Brings Together Global Innovation and Entrepreneurship Leaders

    Published

    on

    Advancing Research Commercialization and Building a Vibrant I&T Ecosystem

    HONG KONG SAR – Media OutReach Newswire – 2 June 2026 – The Hong Kong University of Science and Technology (HKUST) today successfully hosted its annual “Unicorn Day,” one of Hong Kong’s flagship innovation and entrepreneurship events. The event brought together over 1,800 participants, including students, faculty, and alumni, as well as international and local government representatives, industry partners, investors, innovation and technology entrepreneurs, and researchers. Participants exchanged insights on strategies to strengthen collaboration across the innovation ecosystem, foster cross-disciplinary partnerships, and accelerate the translation of research outcomes into real-world impact.

    The event was officiated by Prof. SUN Dong, Secretary for Innovation, Technology and Industry of the HKSAR Government, alongside consuls-generals and senior officials from countries including Australia, Chile, France, Hungary, India, Japan, Malaysia, the Netherlands, Vietnam, and the United Arab Emirates. They were joined by Prof. Nancy IP, HKUST President; Prof. Lionel NI, HKUST (Guangzhou) President; and Prof. Tim CHENG, HKUST Vice-President for Research and Development; in touring over 100 HKUST-nurtured startups, showcasing innovations and applications spanning areas such as healthcare, electronics, and artificial intelligence systems, as well as new materials, green energy, and sustainability.

    Prof. Sun Dong remarked, “Innovation and technology (I&T) has always been at the top of the Hong Kong SAR Government’s agenda. We fully recognise the crucial role of local universities — not only as key partners, but as the bedrock of Hong Kong’s I&T ecosystem. In just three and a half decades, HKUST has risen to become a global powerhouse in deep tech, entrepreneurship, and innovation as demonstrated by its ability to nurture unicorns and deep-tech ventures. Hong Kong is entering a golden era of I&T development. We are building new engines to drive Hong Kong’s high-quality development, focusing on research and development in key fields and leading industry applications. I am confident that Hong Kong will rise as a leading international I&T center and contribute meaningfully to our nation’s high-quality development, and that HKUST will continue to be a driving force in this amazing journey.”

    President Ip said, “As we mark the 35th anniversary of HKUST this year, we also celebrate the spirit of innovation and entrepreneurship that has long been embedded in our DNA. Both the Technology Transfer Center and the Entrepreneurship Center were established in the University’s early years to support faculty and students in realizing their entrepreneurial aspirations and to promote the translation of research outcomes into practical solutions. Over the past 35 years, the University has forged ahead with determination, sowing the seeds of innovation and yielding remarkable achievements across multiple frontier fields. Today, HKUST continues to broaden its horizons, strategically positioning itself in key domains. One example is medical education. The establishment of the HKUST Medical School will integrate the life sciences with cutting-edge technologies to nurture a new generation of interdisciplinary medical professionals.

    Concurrently, HKUST has been actively involved in national initiatives such as the Chang’E 8 lunar exploration mission and research projects for the Tiangong Space Station, and the launch of the first commercially viable aerospace project under the RAISe+ Scheme. These achievements exemplify HKUST’s enduring ‘can do’ spirit over the past decades and echo the theme of today’s event—’From Ideas to Miracles—35 Years of Impact and Beyond’. Looking ahead, HKUST will continue to nurture bold ideas and action, working hand in hand with partners across different sectors to cultivate a vibrant innovation ecosystem, ensuring that research achievements benefit society and create lasting global impact.”

    To support startups in expanding into global markets and to promote cross-border collaboration, HKUST introduced an “International Pavilion,” featuring startups and innovation organizations from various countries and regions. Participants from Thailand, Singapore and Korea were among those represented, strengthening connections between Hong Kong, and countries and regions along the Belt and Road in technology application and industry development.

    The event also saw the signing of multiple partnership agreements, including six strategic collaborations with:

    • GPTX Investment Management Limited
    • China Everbright Water Limited
    • Jiangsu Daotop Environmental Technology
    • Samsung R&D Institute China – Guangzhou
    • CalmCar Physical AI Innovation Center
    • InnoAngel

    to advance talent development and industry–academia integration, and foster innovation-driven research and real-world technology translation.

    HKUST’s I&T Strength Driving Economic Growth

    In addition, HKUST also released the report Driving Socioeconomic Impact Through Research and Innovation: Insights from HKUST, commissioned by the University and prepared by the international research information analytics organization Elsevier. The report highlights HKUST’s outstanding performance in innovation and entrepreneurship. Over the past five years, research output has recorded an average growth of 10%, approximately 9% higher than that of other local institutions. More than 65% of the research is concentrated in engineering and computer science, while 6.2% involves academia-industry collaboration, significantly higher than the global average of 2.7%. These collaborations have translated into impactful intellectual property, with approximately 1,670 patent applications and 700 grants over the same period, and a high IP utilization rate of above 30%.

    Prof. Tim Cheng noted that the findings demonstrate HKUST’s steadily strengthening capabilities in research translation and academia-industry collaboration. HKUST’s publications achieved a Field-Weighted Citation Impact of 4.40, indicating that their citation impact is 4.4 times the global average. This underscores HKUST’s significant contributions to advancing Hong Kong’s socioeconomic development and enhancing its competitiveness in innovation and technology.

    In addition, a “Marketplace” was also featured, showcasing products already launched by startups, including AI analytics tools, healthcare technologies, and smart city solutions, demonstrating the progress of translating research into practical applications.

    Hashtag: #unicorn #unicornday #HKUST #partnership #innovation #startup #tech #AI #space #robotics #materialscience

    The issuer is solely responsible for the content of this announcement.

    Continue Reading

    Trending